Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Financial Officer | August 04, 2026 | August 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date August 04, 2026 · Filed August 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,008 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 1,142 · Balance 66,008 F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 6, 2026 20:34 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | SaleCommon Stock | 1,142 | $1.57 | $1,792.94 |
DisclosureSEC source: 0000905148-26-003499 · form4.xml · nonDerivative · entry 1 Levy Adam D. · CIK 0002061876 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,008 F1 · kind: Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:30 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 46,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002552 · form4.xml · nonDerivative · entry 1 Levy Adam D. · CIK 0002061876 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,150 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:19 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 132,925 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000905148-26-001118 · form4.xml · derivative · entry 1 Levy Adam D. · CIK 0002061876 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,925 Underlying: Common Stock · 132,925 shares Expires 2036-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 21:01 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | PurchaseCommon Stock | 8,832 | $1.70 | $14,999.39 |
DisclosureSEC source: 0000905148-26-000225 · form4.xml · nonDerivative · entry 1 Levy Adam D. · CIK 0002061876 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,983 F1 · price: The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:59 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | Tax withholdingCommon Stock | 1,164 | $1.26 | $1,466.64 |
DisclosureSEC source: 0000905148-25-002732 · form4.xml · nonDerivative · entry 1 Levy Adam D. · CIK 0002061876 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,151 F1 · kind: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:30 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 35,209 | $0.00 Strike: $1.68 | $0.00 |
DisclosureSEC source: 0000905148-25-001075 · form4.xml · derivative · entry 1 Levy Adam D. · CIK 0002061876 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,209 Underlying: Common Stock · 35,209 shares Expires 2035-03-31 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on April 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.